| [1] |
那彦群, 孙光, 叶章群, 等. 2014版中国泌尿外科疾病诊断治疗指南[M]. 北京市: 人民卫生出版社, 2014: 61-89.
|
| [2] |
Center MM, Jernal A, Lortet-Tieulet J, et al. International Variation in Prostate Cancer Incidence and Mortality Rates[J]. Eur Urol, 2012, 61(6): 1079-1092.
|
| [3] |
Siegel R, Miller K, Jemal A. Cancer Statistics, 2018[J]. CA Cancer J Clin, 2018, 68(1): 7-30.
|
| [4] |
Jemal A, Bray F, Center MM, et al. Global cancer statistics[J]. CA Cancer J Clin, 2011, 61(2): 69-90.
|
| [5] |
Clevers H, Nusse R. Wnt/β-catenin signaling and disease[J]. Cell, 2012, 149(6): 1192-1205.
|
| [6] |
Filipovich A, Gehrke I, Poll-Wolbeck SJ, et al. Physiological in hibitors of Wnt signaling[J]. Eur J Haematol, 2011, 86(6): 453-465.
|
| [7] |
Miki T, Yasuda SY, Kahn M. Wnt/beta-catenin signaling in embryonic stem cell self-renewal and somatic cell reprogramming[J]. Stem Cell Rev, 2011, 7(4): 836-846.
|
| [8] |
Voronkov A, Krauss S. Wnt/beta-catenin signaling and small molecule inhibitors[J]. Curr Pharm Des, 2013, 19(4): 634-664.
|
| [9] |
Kahn M. Can we safely target the WNT pathway? [J]. Nat Rev Drug Discov, 2014, 13(7): 513-532.
|
| [10] |
Dolatshad NF, Hellen N, Jabbour RJ, et al. G-protein coupled receptor signaling in pluripotent stem cell-derived cardiovascular cells: implications for disease modeling[J]. Front Cell Dev Biol, 2015, 3(92): 76.
|
| [11] |
Wang Y, Freedman JA, Liu H, et al. Associations between RNA splicing regulatory variants of stemness-related genes and racial disparities in susceptibility to prostate cancer[J]. Int J Cancer, 2017, 141(4): 731-743.
|
| [12] |
Ye J, Chu C, Chen M, et al. TROAP regulates prostate cancer progression via the WNT3/survivin signalling pathways[J]. Oncol Rep, 2019, 41(2): 1169-1179.
|
| [13] |
Li L, Du Z, Gao Y. PLCε knockdown overcomes drug resistance to androgen receptor antagonist in castration-resistant prostate cancer by suppressing the wnt3a/β-catenin pathway[J]. J Cell Physiol, 2019, 26(1): 131-143.
|
| [14] |
Sandsmark E, Hansen AF, Selnæs KM, et al. A novel non-canonical Wnt signature for prostate cancer aggressiveness[J]. Oncotarget, 2017, 8(6): 9572-9586.
|
| [15] |
Chandler JM, Lagasse E. Cancerous stem cells: deviant stem cells with cancer-causing misbehavior[J]. Stem Cell Res Ther, 2010, 1(2):13.
|
| [16] |
Korkaya H, Wicha MS. Cancer stem cells:nature versus nurture[J]. Nat Cell Biol, 2010,12(5): 419-421.
|
| [17] |
Bisson I, Prowse DM. WNT signaling regulates self-renewal and differentiation of prostate cancer cells with stem cell characteristics[J]. Cell Res, 2009, 19(6): 683-697.
|
| [18] |
Korkaya H, Paulson A, Charafe-Jauffret E, et al. Regulation of mammary stem/progenitor cells by PTEN/Akt/beta-catenin signaling[J]. PLoS Biol, 2009, 7(6): e1000121.
|
| [19] |
Wang B-e, Wang X, Long JE,et al. Castration-resistant lgr5+ cells are long-lived stem cells required for prostatic regeneration[J]. Stem Cell Reports, 2015, 4(5): 768-779.
|
| [20] |
Patrawala L, Calhoun T, Schneider-Broussard R, et al.Highly purified CD44+ prostate cancer cells from xenograft human tumors are enriched in tumorigenic and metastatic progenitor cells[J]. Oncogene, 2006, 25(12): 1696-1708.
|
| [21] |
Vatansever HS, Gumus B, Aydogdu O, et al. The role of stem/progenitor cells and Wnt/β-catenin signaling pathway in the patients with prostate cancer[J]. Minerva Urol Nefrol, 2014, 66(4): 249-255.
|
| [22] |
Lee E, Ha S, Logan SK. Divergent androgen receptor and beta-catenin signaling in prostate cancer cells[J]. PloS one, 2015, 10(10): e0141589.
|
| [23] |
Yang X, Chen MW, Terry S, et al. Complex regulation of human androgen receptor expression by Wnt signaling in prostate cancer cells[J]. Oncogene, 2006, 25(24): 3436-3444.
|
| [24] |
Yokoyama NN, Shao S, Hoang BH, et al. Wnt signaling in castration-resistant prostate cancer: Implications for therapy[J]. Am J Clin Exp Urol, 2014, 2(1): 27-44.
|
| [25] |
Robinson D, Van Allen EM, Wu YM, et al.Integrative clinical genomics of advanced prostate cancer[J]. Cell, 2015, 161(5): 1215-1228.
|
| [26] |
Lee SH, Luong R, Johnson DT, et al.Androgen Signaling Is a Confounding Factor for β-catenin-mediated Prostate Tumorigenesis[J]. Oncogene, 2016, 35(6): 702-714.
|
| [27] |
Miyamoto DT, Zheng Y, Wittner BS, et al. RNA-Seq of single prostate CTCs implicates noncanonical Wnt signaling in antiandrogen resistance[J]. Sci, 2015, 349(6254): 1351-1356.
|
| [28] |
Lee GT, Kang DI, Ha YS, et al. Prostate cancer bone metastases acquire resistance to androgen deprivation via WNT5A-mediated BMP-6 induction[J]. Br J cancer, 2014, 110(6): 1634-1644.
|
| [29] |
Takahashi S, Watanabe T, Okada M, et al. Noncanonical Wnt signaling mediates androgen-dependent tumor growth in a mouse model of prostate cancer[J]. Proc Natl Acad Sci U S A, 2011, 108(12): 4938-4943.
|
| [30] |
彭旭，张晓梅，魏诗航，等. 骨髓间充质干细胞向软骨及骨分化：Wnt5a/PCP信号通路作用的研究与进展[J].中国组织工程研究，2016，20(51):7717-7723.
|
| [31] |
李淼沅, 袁润强, 陈业辉. 前列腺癌并骨转移的治疗新进展[J/CD]. 中华腔镜泌尿外科杂志(电子版) 2018, 12(2): 73-75.
|
| [32] |
Bubendorf L, Schopfer A, Wagner U, et al. Metastatic patterns of prostate cancer: an autopsy study of 1,589 patients[J]. Hum Pathol, 2000, 31(5): 578-583.
|
| [33] |
Hall CL, Daignault SD, Shah RB, et al.Dickkopf-1 expression increases early in prostate cancer development and decreases during progression from primary tumor to metastasis[J]. Prostate, 2008, 68(13): 1396-1404.
|
| [34] |
Nandana S, Tripathi M, Duan P, et al.Bone Metastasis of Prostate Cancer Can Be Therapeutically Targeted at the TBX2-WNT Signaling Axis[J]. Cancer Res, 2017, 77(6): 1331-1344.
|
| [35] |
Zheng D, Decker KF, Zhou T, et al.Role of WNT7B-induced noncanonical pathway in advanced prostate cancer[J]. Mol Cancer Res, 2013, 11(5): 482-493.
|
| [36] |
Sebastian A, Hum NR, Hudson BD, et al.Cancer-osteoblast interaction reduces sost expression in osteoblasts and up-regulates lncrna malat1 in prostate cancer[J]. Microarrays(Basel), 2015, 4(4): 503-519.
|
| [37] |
Dai J, Hall CL, Escara-Wilke J, et al. Prostate cancer induces bone metastasis through Wnt-induced bone morphogenetic protein-dependent and independent mechanisms[J]. Cancer Res, 2008, 68(14): 5785-5794.
|
| [38] |
Pacifici R. The Role of IL-17 and TH17 Cells in the Bone Catabolic Activity of PTH[J]. Front Immunol, 2016, 17(7): 57.
|
| [39] |
Huang K, Tang Y, He L, et al. MicroRNA-340 inhibits prostate cancer cell proliferation and metastasis by targeting the MDM2-p53 pathway[J]. Oncol Rep, 2016, 35(2): 887-895.
|
| [40] |
Li Y, Luo H, Xiao N, et al. Long noncoding RNA SChLAP1 accelerates the proliferation and metastasis of prostate cancer via targeting miR-198 and promoting the MAPK1 pathway[J]. Oncol Res, 2018, 26(1): 131-143.
|